| Company Name: |
BOC Sciences |
| Tel: |
1-631-485-4226; 16314854226 |
| Email: |
info@bocsci.com |
|
| | 4H-Pyrazolo[4,3-c]quinolin-4-one, 1,5-dihydro-7-(2-methoxy-3,5-dimethyl-4-pyridinyl)-1-[(3S)-tetrahydro-3-furanyl]- Basic information |
| | 4H-Pyrazolo[4,3-c]quinolin-4-one, 1,5-dihydro-7-(2-methoxy-3,5-dimethyl-4-pyridinyl)-1-[(3S)-tetrahydro-3-furanyl]- Chemical Properties |
| Boiling point | 514.6±50.0 °C(Predicted) | | density | 1.41±0.1 g/cm3(Predicted) | | storage temp. | 4°C, away from moisture and light | | form | Solid | | pka | 12.41±0.20(Predicted) | | color | White to off-white |
| | 4H-Pyrazolo[4,3-c]quinolin-4-one, 1,5-dihydro-7-(2-methoxy-3,5-dimethyl-4-pyridinyl)-1-[(3S)-tetrahydro-3-furanyl]- Usage And Synthesis |
| Uses | Irsenontrine (E2027) is an orally active and selective phosphodiesterase 9 (PDE9) inhibitor. Irsenontrine can be used for the research of neurological diseases[1][2][3]. | | in vivo | Irsenontrine (0.3, 3.3 mg/kg; p.o.) exhibits a significant ameliorative effect on the percentage of exploration of the novel object at 3.3 mg/kg in Scopolamine-induced rats[1].
Irsenontrine (1 mg/kg; p.o.) and memantine hydrochloride (1 mg/kg; p.o.) combined treatment group exhibits a significantly higher percentage of exploration of the novel object than memantine hydrochloride (1 mg/kg) alone[1]. | | References | [1] Miyamoto, et al. Dementia therapeutic agent combining pyrazoloquinoline derivative and memantine. WO2018221550 A1
[2] Hershey LA, et al. Pharmacological Management of Dementia with Lewy Bodies. Drugs Aging. 2019;36(4):309-319. DOI:10.1007/s40266-018-00636-7
[3] Eisai to present latest research on Alzheimer’s disease / dementia pipeline at the 14th international conference on Alzheimer’s & Parkinson’s diseases |
| | 4H-Pyrazolo[4,3-c]quinolin-4-one, 1,5-dihydro-7-(2-methoxy-3,5-dimethyl-4-pyridinyl)-1-[(3S)-tetrahydro-3-furanyl]- Preparation Products And Raw materials |
|